**Name of Journal:** *World Journal of Gastroenterology*

**Manuscript NO:** 47837

**Manuscript Type:** SYSTEMATICREVIEWS

**Small bowel capsule endoscopy and treat-to-target in Crohn's disease: A systematic review**

Le Berre C *et al.* Treat-to-target with capsule endoscopy in CD

Catherine Le Berre, Caroline Trang-Poisson, Arnaud Bourreille

**Catherine Le Berre, Caroline Trang-Poisson, Arnaud Bourreille,** Institut des Maladies de l’Appareil Digestif, Nantes University Hospital, Nantes 44093, France

**ORCID number:**Catherine Le Berre (0000-0002-1124-2019); Caroline Trang-Poisson (0000-0001-9140-5844); Arnaud Bourreille (0000-0003-4903-3535).

**Author contributions:** Le Berre C and Bourreille A designed and performed the literature review and carried out the analysis; Le Berre C drafted the initial manuscript; Bourreille A and Trang-Poisson C critically revised the manuscript for important intellectual content; All authors have read and approved the final version to be published.

**Conflict-of-interest statement:** The authors declare that they have no conflicts of interest.

**PRISMA 2009 Checklist statement:** The authors have read the PRISMA Checklist (2009), and the manuscript was prepared and revised according to the PRISMA 2009 Checklist.

**Open-Access:** This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

**Manuscript source:** Invited manuscript

**Corresponding author: Arnaud Bourreille, MD, PhD, Professor,** Institut des Maladies de l’Appareil Digestif, Nantes University Hospital, 1 place Alexis Ricordeau, Nantes 44093, France. arnaud.bourreille@chu-nantes.fr

**Telephone:** +33-2-40083152

**Fax:** +33-2-40083154

**Received:** March 26, 2019

**Peer-review started:** March 26, 2019

**First decision:** April 11, 2019

**Revised:** May 28, 2019

**Accepted:** July 19, 2019

**Article in press:** July 19, 2019

**Published online:** August 21, 2019

**Abstract**

***BACKGROUND***

Crohn’s disease (CD) can affect the entire gastrointestinal tract. Proximal small bowel (SB) lesions are associated with a significant risk of stricturing disease and multiple abdominal surgeries. The assessment of SB in patients with CD is therefore necessary because it may have a significant impact on prognosis with potential therapeutic implications. Because of the weak correlation that exists between symptoms and endoscopic disease activity, the “treat-to-target” paradigm has been developed, and the associated treatment goal is to achieve and maintain deep remission, encompassing both clinical and endoscopic remission. Small bowel capsule endoscopy (SBCE) allows to visualize the mucosal surface of the entire SB. At that time, there is no recommendation regarding the use of SBCE during follow-up.

***AIM***

To investigate the impact of SBCE in a treat-to-target strategy in patients with CD.

***METHODS***

An electronic literature search was conducted in PubMed and Cochrane library using the following search terms: “capsule endoscopy”, in combination with “Crohn’s disease” and “treat-to-target” or synonyms. Two authors independently reviewed titles and abstracts identified by the search strategy after duplicates were removed. Following the initial screening of abstracts, all articles containing information about SBCE in the context of treat-to-target strategy in patients with CD were included. Full-text articles were retrieved, reference lists were screened manually to identify additional studies.

***RESULTS***

Forty-seven articles were included in this review. Two indexes are currently used to quantify disease activity using SBCE, and there is good correlation between them. SBCE was shown to be useful for disease reclassification in patients who are suspected of having or who are diagnosed with CD, with a significant incremental diagnostic yield compared to other diagnostic modalities. Nine studies also demonstrated that the mucosal healing can be evaluated by SBCE to monitor the effect of medical treatment in patients with CD. This review also demonstrated that SBCE can detect post-operative recurrence to a similar extent as ileocolonoscopy, and proximal SB lesions that are beyond the reach of the colonoscope in over half of the patients.

***CONCLUSION***

SBCE could be incorporated in the treat-to-target algorithm for patients with CD. Randomized controlled trials are required to confirm its usefulness and reliability in this indication.

**Key words:** Wireless capsule endoscopy; Inflammatory bowel disease; Treat-to-target; Monitoring; Mucosal healing; Post-operative recurrence; Prognosis

**© The Author(s) 2019** Published by Baishideng Publishing Group Inc. All rights reserved.

**Core tip:** The treatment goal in patients with Crohn’s disease (CD) combines both clinical and endoscopic remission. Assessment of the small bowel (SB) is substantial because it may have a significant impact on prognosis. Small bowel capsule endoscopy (SBCE) allows direct visualization of the entire SB mucosal surface. We conducted a systematic literature review that aimed to provide a global overview of the studies that assessed the use of SBCE in a treat-to-target strategy in patients with CD. SBCE could be useful for refining the disease location, assessing mucosal healing in patients receiving treatment, and monitoring patients in the post-operative setting.

**Citation:** Le Berre C, Trang-Poisson C, Bourreille A. Small bowel capsule endoscopy and treat-to-target in Crohn's disease: A systematic review. *World J Gastroenterol* 2019; 25(31): 4534-4554 Available from:

**URL**: https://www.wjgnet.com/1007-9327/full/v25/i31/4534.htm

**DOI**: https://dx.doi.org/10.3748/wjg.v25.i31.4534

**INTRODUCTION**

***The prognostic impact of small bowel lesions in Crohn’s disease***

Inflammatory bowel diseases (IBD), which encompasses Crohn’s disease (CD) and ulcerative colitis (UC), are chronic and disabling inflammatory gastrointestinal disorders. In contrast to UC in which lesions are strictly limited to the colon, CD is more heterogeneous and can affect the entire gastrointestinal tract, from the mouth to the anus. The Montreal classification of CD distinguishes anatomical disease location in the ileum (L1), colon (L2), and both the ileum and colon (L3)[1], each accounting for approximately one-third of patients who are diagnosed with CD[2]. About 10%–15% of patients have associated upper gastrointestinal lesions (L4)[3], which are isolated in 2%–3% of cases[4]. It has been demonstrated that jejunal disease is a significantly greater risk factor for stricturing disease and multiple abdominal surgeries than either esophagogastroduodenal or ileal (without proximal) disease[5–7].

***How can the small bowel be assessed in patients with CD?***

Assessment of the small bowel (SB) in patients with suspected or diagnosed CD is necessary because complete visualization of the entire length of the SB may have a significant impact on prognosis with potential therapeutic implications[8]. Device-assisted enteroscopy should be performed only when endoscopic therapy is indicated, because of its invasive nature[9]. Cross-sectional imaging (magnetic resonance enterography and computed tomography enterography) is highly accurate for the diagnosis of obstructive and fistulizing SB CD. Computed tomography enterography (CTE) is less suitable than magnetic resonance enterography (MRE) for follow-up monitoring because radiation exposure should be considered. Since its first approval by the Food and Drug Administration (FDA) in August 2001, small bowel capsule endoscopy (SBCE) has become an important tool for assessing the SB, and it is particularly useful in areas of the gastrointestinal tract that are not accessible to conventional endoscopy. In a recent prospective study assessing whether SBCE or MRE that was performed after the initial diagnosis may alter the original disease classification, SBCE was more sensitive for detection of previously unrecognized locations, while MRE was superior for detection of phenotype shift[10]. Therefore, SBCE and MRE are probably complementary, because MRE assesses transmural involvement, while SBCE allows direct visualization of the mucosal surface of the SB. Five main lesions are associated with CD, although not specific – edema, aphthoid erosions, superficial and deep ulcerations, and stenosis (Figure 1).

***Small bowel capsule endoscopy to monitor patients with CD***

Until recently, therapeutic strategies relied on a progressive and step-wise approach that was based solely on IBD-related symptoms. However, evidence is now accumulating that demonstrates the weak correlation that exists between symptoms and endoscopic disease activity in patients with CD[11–13]. Thus, the “treat-to-target” paradigm was developed in 2015, and it is based on regular and objective assessment of disease activity, and subsequent adjustment of the treatment[14]. The treatment goal has evolved to a new concept, which is achieving and maintaining deep remission, combining both clinical and endoscopic remission[15]. In patients with CD, the STRIDE consensus defined endoscopic remission as resolution of ulceration at ileocolonoscopy or resolution of inflammation findings on cross-sectional imaging when endoscopy cannot adequately evaluate inflammation[15]. However, as discussed above, MRE may often underestimate mucosal lesions, and SBCE could play a key role to play in this tight monitoring of patients with CD.

Both European and American guidelines now recognize SBCE as a useful adjunct in diagnosising SB CD in patients in whom there is a high clinical suspicion for CD, because it has a high negative predictive value in this indication[9,16]. In 2009, an international consensus aimed to define the role of SBCE in the follow-up of patients with IBD, suggesting that SBCE “may identify lesions in the small bowel that have not been detected by ileocolonoscopy after ileocolic resection” and that it “has a potential role in the assessment of mucosal healing after drug therapy”, but there was little of evidence to support this suggestion[17]. At that time, there is no recommendation for the use of SBCE during patient follow-up.

***Objective***

Here, we conducted a systematic literature review that aimed to investigate the impact of SBCE in a treat-to-target strategy in patients with CD.

**MATERIALS AND METHODS**

***Search strategy***

An electronic literature search was conducted in PubMed and the Cochrane library using the following search terms: “capsule endoscopy”, in combination with “Crohn’s disease” or “inflammatory bowel disease” or “ileitis” or “enteritis”, and with synonyms of “treat-to-target” or “monitoring” or “post-operative recurrence”. The search was conducted in early February 2019 and included citations beginning from January 1, 2000. We restricted our search to studies that were published in English and we excluded studies related to animal research. Supplementary Table 1 provides the PubMed literature search strategy in detail. Duplicate articles identified in both PubMed and Cochrane library were manually deleted. To identify additional relevant studies, we checked the reference lists of the selected articles.

***Study selection and data extraction***

Two authors independently reviewed the titles and abstracts of articles that were identified by the search strategy after duplicates were removed (CLB and AB). Any disagreements regarding the inclusion of articles were solved by discussion until consensus was reached. Reviewers were not blinded to the study authors’ affiliation or journal name. Following the initial screening of abstracts, all articles containing information about SBCE in the context of treat-to-target strategy in patients with CD were included. Studies without any outcome related to treat-to-target strategy or to CD were excluded, as were studies related to pediatric populations and reviews, meta-analyses, editorials, and letters to the editor. Full-text articles were retrieved, and reference lists were screened manually to identify additional studies.

The following data were extracted for each included study: name of the first author, year of publication, study design, patient population and sample size, capsule endoscopy findings, and comparator modality, if applicable. For studies assessing disease reclassification, the impact of SBCE findings in patient management was reported. For studies assessing mucosal healing during treatment, ongoing treatment and prior biologic exposure were noted. For studies assessing the use of SBCE in the post-operative setting, risk factors for post-operative recurrence, indications for surgery, interval between surgery and endoscopic re-assessment, post-operative prophylactic treatment, and the rate of clinical recurrence were noted.

***Data presentation***

The PRISMA Statement for Reporting Systematic Reviews and Meta-Analyses was used to conduct and report the results of this review[18]. The first part of this systematic review focused on the indexes that were used to describe CD lesions at small bowel capsule endoscopy. The findings were then organized according to the context of SBCE use when monitoring a patient who was diagnosed with inflammatory bowel disease, as follows: (1) reclassifying disease location or phenotype; (2) assessing mucosal healing in patients with CD; and (3) monitoring patients in the post-operative setting.

**RESULTS**

***Literature search results***

There were 153 studies identified after the electronic search. Seven additional studies were identified from a review of the reference lists from included articles. Based on the information provided in the abstracts, 103 studies were excluded, as well as seven duplicates. Fifty articles were then selected for full-text review. Among those articles, three were excluded, and 47 articles were finally included in this review. The PRISMA diagram describing the article search process is presented in Figure 2.

***Indexes (nine studies)***

Supplementary Table 2 summarizes the studies that assessed the two indexes that have been developed to date to describe CD lesions at SBCE. The first index is the Lewis score, which was developed in 2007[19] and validated in 2014, and it has excellent interobserver agreement in patients with known SB CD[20]. A score below 135 is considered to be normal, while a score above 790 reflects moderate to severe inflammation. Between these two values, SB inflammation is considered to be mild[19]. This score was also useful as a diagnostic tool for patients with suspected CD, with a sensitivity and positive predictive value of 82.6%, and a specificity and negative predictive value of 87.9%[21].

The second index was developed in 2008 and it is called Capsule Endoscopy Crohn’s Disease Activity Index (CECDAI). It ranges from 0 to 36, and the correlation between two observers is also excellent[22]. This score was validated in 2012 in a cohort of 50 patients with known SB CD[23]. Two recent studies showed a significant correlation between the Lewis and CECDAI scores in patients with known SB CD, with correlation coefficients of *r =* 0.632 (*P <* 0.0001)[24] and *r =* 0.81 (*P =* 0.0001)[25], respectively. Lewis score thresholds of 135 and 790 correspond with CECDAI levels of 3.8 and 5.8, respectively[24].

Compared to the MRE scores, the Lewis score was significantly correlated with both MaRIA and Clermont scores (*r =* 0.50, *P =* 0.001 and *r =* 0.53, *P =* 0.001, respectively), especially for detecting moderate to severe inflammation[26]. However, the Lewis score was weakly correlated with clinical activity as measured by the Harvey Bradshaw index (*r =* 0.213, *P =* 0.019) and no correlation was found between CD activity index (CDAI) and the CECDAI[23]. The Lewis score moderately correlated with C-reactive protein (*r =* 0.326, *P <* 0.001)[27], and a moderate correlation was demonstrated between SBCE scores and fecal calprotectin (*r =* 0.48, *P =* 0.001 for Lewis score, and *r =* 0.53, *P =* 0.001 for CECDAI)[25].

***Disease reclassification and prognosis (22 studies)***

Table 1 describes the key studies that show the potential impact of SBCE on disease reclassification of patients suspected or diagnosed with IBD, and gives an overview of the subsequent therapeutic management. Most of those studies focused on reclassifying the CD location by assessing SB in patients with known or suspected CD. All showed positive SBCE findings, including jejunal lesions that had not previously been visualized using conventional endoscopy or imaging. All of the studies that compared SBCE to other diagnostic modalities showed a significant incremental diagnostic yield of SBCE. Compared to push enteroscopy, SBCE had an incremental diagnostic yield of 63.6% in patients with known CD, although the difference was not significant in patients with suspected CD[28]. Two studies compared the diagnostic yield of SBCE to that of enteroclysis, and both demonstrated a significant incremental diagnostic yield of 62.0%[28] and 33.4%[29] in patients with known CD. In patients with suspected CD and negative ileocolonoscopy, an intestinal ultrasound and SBCE had a similar diagnostic yield (38%)[30]. However, in patients with known CD of the distal ileum, SBCE had an incremental diagnostic yield of 41% compared to the small intestine contrast ultrasonography (SICUS) for the detection of upper SB lesions, while the detection rate of distal SB lesions was similar for both modalities (93%)[31]. Compared to cross-sectional imaging, three studies demonstrated that SBCE was superior in detecting SB lesions[10,32,33], with an incremental diagnostic yield up to 31.9%[33], especially for the detection of proximal SB CD location[10,33]. However, the lesions that were considered for the diagnosis of CD varied greatly from one study to another, making it difficult to compare these studies.

A single study focused on the comparison of SBCE findings between CD patients with and without perianal disease, showing that patients with perianal involvement had significantly more relevant SB lesions (94.1% *vs* 66.6%, *P =* 0.03) and higher inflammatory activity with a Lewis score ≥ 135 (94.1% *vs* 64.8%, *P =* 0.03), especially in proximal SB segments, compared to patients without perianal CD[34].

Only three of the included studies focused on reclassifying the IBD type in patients who were diagnosed with IBD-unclassified, indeterminate colitis or pouchitis. The lesions that were considered for the diagnosis of CD were very different depending on the study. However, SBCE detected SB lesions allowing the physician to suspect or even make the diagnosis of CD in 16.7% to 50.0% of patients with IBD-unclassified or indeterminate colitis, and up to 65.2% of patients who were diagnosed with pouchitis following ileo-anal anastomosis[35–37].

For the impact on therapeutic management, most of the studies showed that SBCE findings led to a change in the dose or change of immunomodulatory agent, initiation of biologic treatment, or avoidance of surgery, in more than one-third of patients, and even in 100% of patients in four studies[38–41].

***Assessing mucosal healing in patients with CD (nine studies)***

Table 2 summarizes the nine studies that evaluated the use of SBCE to assess mucosal healing in patients who were diagnosed with CD. All but one study had a prospective design. Most of these studies did not evaluate a specific treatment, except for two studies, one of which focused on adalimumab and azathioprine[42] and the other that focused on certolizumab pegol[43]. Another study was a sub-study of a prospective, randomized, double blind placebo-controlled study that assessed the safety, tolerability and efficacy of glatiramer acetate (Copaxone®)[44]. In three of the nine included studies, there was no comparison between SBCE findings at baseline and during follow-up, because the included patients—most of whom were in clinical remission—had only one SBCE after treatment[45–47]. The SBCE findings that were considered for the assessment of mucosal healing differed according to the studies, although most of them were based on the calculation of the Lewis score, with a normal value below 135.

Overall, despite high heterogeneity in these studies, the results indicated that mucosal healing can be evaluated by SBCE to monitor the effect of medical treatment in patients with CD, with a significant correlation between the Lewis score and fecal calprotectin (*r =* 0.82, *P <* 0.0001)[46], while there was no significant correlation between this score and clinical activity as measured by the CDAI[44,47].

***Monitoring patients with CD in the post-operative setting (seven studies)***

Only seven of the included studies focused on the monitoring of patients with CD in the post-operative setting. The results are summarized in Table 3. All but one of the studies were prospective, and they all had small-sized cohorts with less than 35 patients. The single retrospective study included 83 patients with no risk factor for post-operative recurrence. The design methodology varied greatly between studies, making them difficult to compare. First, indications for surgery were different depending on the study, with varying proportions of treatment failure, stenosis, and fistula or abscess. The existence of risk factors for post-operative recurrence was also variable between studies, especially for smoking (range, 11%–50%) and penetrating phenotype (range, 7%–58%). In some studies, post-operative prophylactic treatment was forbidden, while others allowed the use of immunosuppressive drugs or biologics. The interval between surgery and the endoscopic re-assessment was also extremely variable, ranging from less than 3 mo to 1 year. Finally, SBCE findings that were considered for defining post-operative recurrence were also different across studies, and they were mostly based on the Lewis score (≥ 135) or the Rutgeerts score (≥ i,1 or i,2)[48].

All but one study compared SBCE to ileocolonoscopy, which is the current gold standard for assessing post-operative recurrence in patients with CD. Although two studies showed that the sensitivity of SBCE in detecting recurrence in the neoterminal ileum was not superior to that of ileocolonoscopy[49,50], the other studies showed that SBCE could detect post-operative recurrence more frequently than ileocolonoscopy[51–54], and with a better tolerance[51]. Moreover, two studies demonstrated that SBCE detected lesions outside the scope of ileocolonoscopy in more than half of the patients[49,51], which might be a substantial advantage as compared to conventional endoscopy because of the prognostic impact of these lesions on therapeutic management.

The retrospective study was also interesting and evaluated the impact of SBCE findings on clinical outcomes in asymptomatic patients without medical prophylaxis after ileocolonic resection. Two groups of patients were compared. Group 1 underwent ileocolonoscopy and SBCE within 1 year after surgery, whereas group 2 only had ileocolonoscopy. Patients with endoscopic recurrence detected by either ileocolonoscopy or SBCE received azathioprine or infliximab. One year later, disease activity was re-assessed by ileocolonoscopy. The clinical recurrence rate was 2.7% in group 1 compared with 21.7% in group 2 (*P =* 0.019), and the endoscopic recurrence rates were 21.6% and 43.5% (*P =* 0.036), respectively[54], suggesting that SBCE could be useful in detecting post-operative recurrence especially in patients without pharmacological prophylaxis.

This is reinforced by the results of another study that aimed to assess residual SB lesions in 25 CD patients immediately after surgery (< 3 mo). The mean Lewis score was 751.3, and 84.0% had endoscopic activity, and these residual lesions, especially in the distal SB, were associated with postoperative clinical recurrence[55], suggesting that SBCE could be used to detect very early post-operative recurrence, particularly in patients without any risk factors who do not necessarily require prophylactic treatment according to the current guidelines.

**DISCUSSION**

This systematic review aimed to provide a global overview of the published data on the use of SBCE for close monitoring of patients with CD. In a treat-to-target strategy, SBCE could be useful for refining disease location and prognosis, assessing mucosal healing in patients receiving treatment, and monitoring patients in the post-operative setting.

In contrast to disease phenotype that has long been recognized as an independent risk factor for poor outcome when complicated, disease location was not considered to be substantial in defining disease prognosis until recently. Several studies have now demonstrated that jejunal disease is associated with an increased risk of stricturing disease and abdominal surgeries as compared to either esophagogastroduodenal (EGD) or ileocolonic disease[5–7]. Clarity in disease distribution is therefore crucial, and pediatricians have already modified and modernized the Montreal classification, all the more so as upper gastrointestinal involvement is much more frequent in children than in adults (30%-80% *vs* 10%-15%). The Paris classification tried to avoid any ambiguity in the meaning of upper gastrointestinal lesions (L4), by distinguishing the lesions that are proximal to the ligament of Treitz (L4a) and those that are distal to the ligament of Treitz but proximal to the distal one-third of the ileum (L4b)[56]. Further characterization of the L4 phenotype in the Montreal classification into three specific subgroups including L4-EGD, L4-jejunal, and L4-proximal ileal disease may be warranted, similar to the Paris classification of pediatric patients. This was suggested by a recent retrospective cohort study in which L4 disease had a worse prognosis compared to non-L4 disease, and within L4 disease, the phenotype of L4-jejunal and L4-proximal ileal disease indicated a higher risk for intestinal surgery[57]. Thus, SBCE could be particularly appropriate to detect lesions outside the scope of conventional endoscopy because it seems to be more sensitive than imaging to detect a previously unrecognized disease location[10]. Similarly, SBCE could also be valuable in patients with IBD-U, indeterminate colitis or pouchitis, as it may lead to the diagnosis of CD in up to two-thirds of patients, impacting the therapeutic management in most cases.

With the advent of the treat-to-target paradigm in IBD patients, endoscopic remission has become part of the therapeutic goal, combined with clinical remission, leading to the concept of “deep remission”. Given the weak correlation that exists between symptoms and endoscopic disease activity in patients with CD, the STRIDE consensus recommended assessment of endoscopic activity at 6- to 9-mo intervals during the active phase of CD[15]. Thus, SBCE appears to be more feasible as compared to conventional endoscopy, with better patient acceptance, and more sensitive to assess mucosal inflammation than cross-sectional imaging. This review showed that mucosal healing can be assessed by SBCE to monitor the effect of medical treatment in patients with CD, with a significant correlation between the Lewis score and fecal calprotectin (*r =* 0.82, *P <* 0.0001)[46]. However, the definition of endoscopic remission as assessed by SBCE remains unknown because there is currently no consensus on the therapeutic objective to reach in luminal SB CD (normalization of SBCE or absence of deep or superficial ulcerations). Similarly, endoscopic re-assessment should be timely in the post-operative setting to detect post-operative recurrence at an early stage. Ileocolonoscopy remains the gold standard for this indication and it is recommended within the first year after surgery, when treatment decisions may be affected[58]. This review demonstrated that SBCE could effectively detect post-operative recurrence to a similar extent as ileocolonoscopy, and that it can detect proximal SB lesions beyond the reach of the colonoscope in more than half of the patients[49,51]. SBCE could be used to detect very early post-operative recurrence especially in patients without any risk factors who do not necessarily require pharmacological prophylaxis immediately after surgery[54,55].

Randomized controlled trials are required to confirm the usefulness and reliability of SBCE in such indications before its incorporation in treat-to-target algorithms. However, validated criteria for the diagnosis of CD at SBCE are needed because some studies have questioned the specificity of SBCE findings for CD, and to date, the lesions that are used to define CD vary greatly across studies. A panel of international experts is currently putting together a three-round Delphi consensus to define exactly which SBCE findings constitute a diagnosis of CD, as has been done recently for the terminology and description of the most frequent and relevant vascular lesions in SBCE[59]. These terms and descriptions will be useful for both medical research and daily practice.

In addition, the practical modalities of performing SBCE may highly influence the results. There are currently five available CE systems to explore the SB: PillCam SB3 (Medtronic, Dublin, Ireland), EndoCapsule (Olympus, Tokyo, Japan), MiroCam (Intromedic, Seoul, South Korea), CapsoCam (CapsoVision, Saratoga, United States), and the Pillcam COLON2 (Medtronic, Dublin, Ireland). The Pillcam COLON2 also visualizes the SB, even though it was designed to explore the colon. Although all these devices are based on comparable technologies, significant differences exist in the number of cameras, frame rate, field of view, viewing direction, image resolution and battery life[60]. These differences could theoretically influence diagnostic performance, but there are currently no available head-to-head studies comparing these devices in patients with CD. Most of studies have been performed using the PillCam SB because this CE system has dominated the world market for many years.

In addition to the choice of the CE system, SB preparation before the SBCE may improve visualization, diagnostic sensitivity, and transit time. Optimal SB preparation remains controversial. Multiple studies examined the effect of different bowel cleansing regimens on mucosal visualization, diagnostic yield and completion rates, and several meta-analyses tried to determine the best strategy, but conflicting results have been obtained[61–64]. Prokinetics do not seem to improve the diagnostic yield and should probably not be used[62,63]. Simethicone and laxatives, including polyethylene glycol (PEG) and sodium phosphate, could be used because they seem to improve SB quality visualization. However, their effect on diagnostic yield remains controversial[61,63-65]. A recent study demonstrated in a cohort of 860 patients that clear liquid fasting had similar preparation quality and diagnostic yield compared to a 2-L PEG protocol[66]. Thus, there is still no consensus on the use of bowel cleansing before SBCE in patients examined for CD.

Reading protocols might also impact the diagnostic accuracy of SBCE. Time-consuming video analysis is a substantial limitation of using SBCE in daily practice, and the available software, Given RAPID Reader®, for SBCE analysis has developed several techniques to shorten reading times. Physicians can first modify the viewing mode from single to dual or quad view, and the frame rate can be adjusted from 5 to 40 frames per second (fr/s). A recent study compared a single view, dual view, and quad view at different frame rates using a SB video sequence with 60 pathological images of SB angioectasias, and it showed that both viewing mode and frame rate significantly influence lesion detection, with an increase in detection rate using the dual and quad view compared to single view, but a decrease in the number of positive findings when increasing the frame rate[67]. However, for CD, increasing the viewing speed may be feasible, as illustrated by another study in which overlooked lesions did not change the final result of the examination[68], given that CD lesions are multiple and often widespread in the SB. Another way to shorten reading times is to use the Quickview function provided by Given RAPID Reader® which filters and reduces the number of images shown to the capsule endoscopist based on a specific algorithm that was developed by the manufacturer. Sampling rates between 2% and 80% can be chosen. A recent study showed that the frequencies of the selected lesions picked up by Quickview mode using percentages for sensitivity settings of 5%, 15%, 25%, and 35% were 61%, 74%, 93%, and 98%, respectively. With a 25% sampling rate, only 7% of lesions were missed, and the reading time was reduced by approximately 50%[69]. Two other studies showed that despite a significant number of missed lesions, Quickview mode is a safe and time‐reducing method for diagnosing SB CD[70,71].

Finally, discontinuation of nonsteroidal anti-inflammatory drugs (NSAIDs) is recommended at least 1 mo before SBCE because these drugs may induce SB mucosal lesions that are indistinguishable from those caused by CD[72].

This review showed that CE allows a direct and detailed evaluation of the entire SB mucosa with detection of the earliest CD lesions compared to imaging modalities, with the advantage of being a patient-friendly and noninvasive procedure. SBCE also proved to be cost-effective[73,74]. However, there are some limitations (Table 4), of which capsule retention is the main concern. For this risk, the European Society of Gastrointestinal Endoscopy (ESGE) does not recommend routine use of the PillCam patency capsule before SBCE in patients with suspected CD without any obstructive symptoms. When SBCE is indicated in patients with established CD, ESGE recommends prior use of the Agile capsule to confirm functional patency of the SB[72]. Available data suggest that the PillCam patency capsule is a safe method for testing SB patency before SBCE, even in patients with a radiologically confirmed stricture[75], because symptomatic patency capsule retention is a very rare complication with a favorable prognosis, as demonstrated in a multicenter retrospective case series of 1615 cases[76].

Taken together, the results of this systematic review demonstrate that SBCE might be used for close monitoring and incorporated into the treat-to-target algorithm for patients diagnosed with CD, in order to regularly evaluate disease activity (Figure 3). The development of pan-enteric video capsule endoscopy should allow broadening of the indications for SBCE in patients with CD[77]. Finally, artificial intelligence is expected to help reduce the burden on capsule endoscopists by automatically detecting and classifying lesions with the development of deep learning systems.

This systematic review aimed to provide a global overview of the potential applications of SBCE in a treat-to-target strategy in patients with CD. SBCE should, therefore, be useful for classifying disease location at baseline, with a prognostic impact of proximal SB lesions. SBCE may also allow physicians to assess the achievement of endoscopic remission in patients receiving treatment, and to detect early post-operative recurrence. However, randomized controlled trials are required to confirm the usefulness and reliability of SBCE for these indications, and validated criteria for the diagnosis of CD at SBCE are eagerly awaited.

**ARTICLE HIGHLIGHTS**

***Research background***

Crohn’s disease (CD) may affect any part of the digestive tract. Proximal small bowel (SB) lesions, especially jejunal lesions, are associated with an increased risk of stricturing disease and abdominal surgeries compared to esophagogastroduodenal or ileocolonic disease. Thus, assessing the SB may have a significant impact on prognosis. The treat-to-target paradigm was developed in 2015 because of the poor correlation that exists between symptoms and endoscopic disease activity in patients with CD. This concept is based on regular and objective assessment of disease activity and subsequent adjustment of treatment, with the final aim of reaching both clinical and endoscopic remission. Until now, the treat-to-target strategy is based on the assessment of mucosal lesions seen by endoscopy into the ileum and the colon and for the SB by trans-sectional imaging techniques.

***Research motivation***

The small bowel capsule endoscopy (SBCE) has a higher diagnostic yield compared to the imaging techniques such as the magnetic resonance imaging with enterography (MRE) to detect mucosal lesions especially for the proximal part of the SB and might be more accurate in a treat-to-target strategy. SBCE and MRE are probably complementary, as MRE assesses transmural involvement, while SBCE allows a direct visualization of the mucosal surface of the entire SB. However, there is no recommendation regarding the use of SBCE during patient follow-up.

***Research objectives***

To investigate the impact of SBCE in a treat-to-target strategy in patients with CD.

***Research methods***

An electronic search of the literature was conducted using PubMed and Cochrane library focusing on studies regarding SBCE in the tight monitoring of patients with CD. All articles containing information about SBCE in the context of treat-to-target strategy in patients with CD were included. Full-text articles were retrieved, reference lists were screened manually to identify additional studies.

***Research results***

Forty-seven articles were included in total. Twenty-two studies demonstrated the usefulness of SBCE on disease reclassification of patients suspected or diagnosed with CD, with a significant incremental diagnostic yield compared to other diagnostic modalities. Nine studies showed that mucosal healing can be evaluated by SBCE to monitor the effect of medical treatment. Seven studies demonstrated that SBCE could detect post-operative recurrence to a similar extent as ileocolonoscopy, and proximal SB lesions beyond the reach of the colonoscope in more than half of the patients.

***Research conclusions***

This systematic review provided a global overview of the published studies assessing the use of SBCE in the tight monitoring of patients with CD. SBCE might be incorporated in the treat-to-target algorithm and could be useful for refining disease location and prognosis, assessing mucosal healing in patients under treatment, and monitoring patients in the post-operative setting.

***Research perspectives***

Randomized controlled trials are required to confirm the reliability of SBCE in the treat-to-target algorithm of patients with CD. In addition, the development of pan-enteric video capsule endoscopy should allow to broaden its indications, all the more so as artificial intelligence is expected to help reduce the burden of capsule endoscopists by automatically detecting and classifying lesions.

**REFERENCES**

1 **Silverberg MS**, Satsangi J, Ahmad T, Arnott ID, Bernstein CN, Brant SR, Caprilli R, Colombel JF, Gasche C, Geboes K, Jewell DP, Karban A, Loftus EV Jr, Peña AS, Riddell RH, Sachar DB, Schreiber S, Steinhart AH, Targan SR, Vermeire S, Warren BF. Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a Working Party of the 2005 Montreal World Congress of Gastroenterology. *Can J Gastroenterol* 2005; **19** Suppl A: 5A-36A [PMID: 16151544]

2 **Gasche C**, Scholmerich J, Brynskov J, D'Haens G, Hanauer SB, Irvine EJ, Jewell DP, Rachmilewitz D, Sachar DB, Sandborn WJ, Sutherland LR. A simple classification of Crohn's disease: report of the Working Party for the World Congresses of Gastroenterology, Vienna 1998. *Inflamm Bowel Dis* 2000; **6**: 8-15 [PMID: 10701144]

3 **Cosnes J**, Gower-Rousseau C, Seksik P, Cortot A. Epidemiology and natural history of inflammatory bowel diseases. *Gastroenterology* 2011; **140**: 1785-1794 [PMID: 21530745 DOI: 10.1053/j.gastro.2011.01.055]

4 **Rutgeerts P**, Onette E, Vantrappen G, Geboes K, Broeckaert L, Talloen L. Crohn's disease of the stomach and duodenum: A clinical study with emphasis on the value of endoscopy and endoscopic biopsies. *Endoscopy* 1980; **12**: 288-294 [PMID: 7428736 DOI: 10.1055/s-2007-1021762]

5 **Lazarev M**, Huang C, Bitton A, Cho JH, Duerr RH, McGovern DP, Proctor DD, Regueiro M, Rioux JD, Schumm PP, Taylor KD, Silverberg MS, Steinhart AH, Hutfless S, Brant SR. Relationship between proximal Crohn's disease location and disease behavior and surgery: a cross-sectional study of the IBD Genetics Consortium. *Am J Gastroenterol* 2013; **108**: 106-112 [PMID: 23229423 DOI: 10.1038/ajg.2012.389]

6 **Wolters FL**, Russel MG, Sijbrandij J, Ambergen T, Odes S, Riis L, Langholz E, Politi P, Qasim A, Koutroubakis I, Tsianos E, Vermeire S, Freitas J, van Zeijl G, Hoie O, Bernklev T, Beltrami M, Rodriguez D, Stockbrügger RW, Moum B. Phenotype at diagnosis predicts recurrence rates in Crohn's disease. *Gut* 2006; **55**: 1124-1130 [PMID: 16361306 DOI: 10.1136/gut.2005.084061]

7 **Chow DK**, Sung JJ, Wu JC, Tsoi KK, Leong RW, Chan FK. Upper gastrointestinal tract phenotype of Crohn's disease is associated with early surgery and further hospitalization. *Inflamm Bowel Dis* 2009; **15**: 551-557 [PMID: 19067420 DOI: 10.1002/ibd.20804]

8 **Kopylov U**, Ben-Horin S, Seidman EG, Eliakim R. Video Capsule Endoscopy of the Small Bowel for Monitoring of Crohn's Disease. *Inflamm Bowel Dis* 2015; **21**: 2726-2735 [PMID: 26193349 DOI: 10.1097/MIB.0000000000000497]

9 **Gomollón F**, Dignass A, Annese V, Tilg H, Van Assche G, Lindsay JO, Peyrin-Biroulet L, Cullen GJ, Daperno M, Kucharzik T, Rieder F, Almer S, Armuzzi A, Harbord M, Langhorst J, Sans M, Chowers Y, Fiorino G, Juillerat P, Mantzaris GJ, Rizzello F, Vavricka S, Gionchetti P; ECCO. 3rd European Evidence-based Consensus on the Diagnosis and Management of Crohn's Disease 2016: Part 1: Diagnosis and Medical Management. *J Crohns Colitis* 2017; **11**: 3-25 [PMID: 27660341 DOI: 10.1093/ecco-jcc/jjw168]

10 **Greener T**, Klang E, Yablecovitch D, Lahat A, Neuman S, Levhar N, Avidan B, Yanai H, Dotan I, Chowers Y, Weiss B, Saibil F, Amitai MM, Ben-Horin S, Kopylov U, Eliakim R; Israeli IBD Research Nucleus (IIRN). The Impact of Magnetic Resonance Enterography and Capsule Endoscopy on the Re-classification of Disease in Patients with Known Crohn's Disease: A Prospective Israeli IBD Research Nucleus (IIRN) Study. *J Crohns Colitis* 2016; **10**: 525-531 [PMID: 26748404 DOI: 10.1093/ecco-jcc/jjw006]

11 **Modigliani R**, Mary JY, Simon JF, Cortot A, Soule JC, Gendre JP, Rene E. Clinical, biological, and endoscopic picture of attacks of Crohn's disease. Evolution on prednisolone. Groupe d'Etude Thérapeutique des Affections Inflammatoires Digestives. *Gastroenterology* 1990; **98**: 811-818 [PMID: 2179031]

12 **Cellier C**, Sahmoud T, Froguel E, Adenis A, Belaiche J, Bretagne JF, Florent C, Bouvry M, Mary JY, Modigliani R. Correlations between clinical activity, endoscopic severity, and biological parameters in colonic or ileocolonic Crohn's disease. A prospective multicentre study of 121 cases. The Groupe d'Etudes Thérapeutiques des Affections Inflammatoires Digestives. *Gut* 1994; **35**: 231-235 [PMID: 7508411]

13 **Peyrin-Biroulet L**, Reinisch W, Colombel JF, Mantzaris GJ, Kornbluth A, Diamond R, Rutgeerts P, Tang LK, Cornillie FJ, Sandborn WJ. Clinical disease activity, C-reactive protein normalisation and mucosal healing in Crohn's disease in the SONIC trial. *Gut* 2014; **63**: 88-95 [PMID: 23974954 DOI: 10.1136/gutjnl-2013-304984]

14 **Bouguen G**, Levesque BG, Feagan BG, Kavanaugh A, Peyrin-Biroulet L, Colombel JF, Hanauer SB, Sandborn WJ. Treat to target: a proposed new paradigm for the management of Crohn's disease. *Clin Gastroenterol Hepatol* 2015; **13**: 1042-50.e2 [PMID: 24036054 DOI: 10.1016/j.cgh.2013.09.006]

15 **Peyrin-Biroulet L**, Sandborn W, Sands BE, Reinisch W, Bemelman W, Bryant RV, D'Haens G, Dotan I, Dubinsky M, Feagan B, Fiorino G, Gearry R, Krishnareddy S, Lakatos PL, Loftus EV Jr, Marteau P, Munkholm P, Murdoch TB, Ordás I, Panaccione R, Riddell RH, Ruel J, Rubin DT, Samaan M, Siegel CA, Silverberg MS, Stoker J, Schreiber S, Travis S, Van Assche G, Danese S, Panes J, Bouguen G, O'Donnell S, Pariente B, Winer S, Hanauer S, Colombel JF. Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): Determining Therapeutic Goals for Treat-to-Target. *Am J Gastroenterol* 2015; **110**: 1324-1338 [PMID: 26303131 DOI: 10.1038/ajg.2015.233]

16 **Lichtenstein GR**, Loftus EV, Isaacs KL, Regueiro MD, Gerson LB, Sands BE. ACG Clinical Guideline: Management of Crohn's Disease in Adults. *Am J Gastroenterol* 2018; **113**: 481-517 [PMID: 29610508 DOI: 10.1038/ajg.2018.27]

17 **Bourreille A**, Ignjatovic A, Aabakken L, Loftus EV Jr, Eliakim R, Pennazio M, Bouhnik Y, Seidman E, Keuchel M, Albert JG, Ardizzone S, Bar-Meir S, Bisschops R, Despott EJ, Fortun PF, Heuschkel R, Kammermeier J, Leighton JA, Mantzaris GJ, Moussata D, Lo S, Paulsen V, Panés J, Radford-Smith G, Reinisch W, Rondonotti E, Sanders DS, Swoger JM, Yamamoto H, Travis S, Colombel JF, Van Gossum A; World Organisation of Digestive Endoscopy (OMED) and the European Crohn's and Colitis Organisation (ECCO). Role of small-bowel endoscopy in the management of patients with inflammatory bowel disease: an international OMED-ECCO consensus. *Endoscopy* 2009; **41**: 618-637 [PMID: 19588292 DOI: 10.1055/s-0029-1214790]

18 **Liberati A**, Altman DG, Tetzlaff J, Mulrow C, Gøtzsche PC, Ioannidis JP, Clarke M, Devereaux PJ, Kleijnen J, Moher D. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. *Ann Intern Med* 2009; **151**: W65-W94 [PMID: 19622512]

19 **Gralnek IM**, Defranchis R, Seidman E, Leighton JA, Legnani P, Lewis BS. Development of a capsule endoscopy scoring index for small bowel mucosal inflammatory change. *Aliment Pharmacol Ther* 2008; **27**: 146-154 [PMID: 17956598 DOI: 10.1111/j.1365-2036.2007.03556.x]

20 **Cotter J**, Dias de Castro F, Magalhães J, Moreira MJ, Rosa B. Validation of the Lewis score for the evaluation of small-bowel Crohn's disease activity. *Endoscopy* 2015; **47**: 330-335 [PMID: 25412092 DOI: 10.1055/s-0034-1390894]

21 **Rosa B**, Moreira MJ, Rebelo A, Cotter J. Lewis Score: a useful clinical tool for patients with suspected Crohn's Disease submitted to capsule endoscopy. *J Crohns Colitis* 2012; **6**: 692-697 [PMID: 22398099 DOI: 10.1016/j.crohns.2011.12.002]

22 **Gal E**, Geller A, Fraser G, Levi Z, Niv Y. Assessment and validation of the new capsule endoscopy Crohn's disease activity index (CECDAI). *Dig Dis Sci* 2008; **53**: 1933-1937 [PMID: 18034304 DOI: 10.1007/s10620-007-0084-y]

23 **Niv Y**, Ilani S, Levi Z, Hershkowitz M, Niv E, Fireman Z, O'Donnel S, O'Morain C, Eliakim R, Scapa E, Kalantzis N, Kalantzis C, Apostolopoulos P, Gal E. Validation of the Capsule Endoscopy Crohn's Disease Activity Index (CECDAI or Niv score): a multicenter prospective study. *Endoscopy* 2012; **44**: 21-26 [PMID: 22125196 DOI: 10.1055/s-0031-1291385]

24 **Koulaouzidis A**, Douglas S, Plevris JN. Lewis score correlates more closely with fecal calprotectin than Capsule Endoscopy Crohn's Disease Activity Index. *Dig Dis Sci* 2012; **57**: 987-993 [PMID: 22057284 DOI: 10.1007/s10620-011-1956-8]

25 **Yablecovitch D**, Lahat A, Neuman S, Levhar N, Avidan B, Ben-Horin S, Eliakim R, Kopylov U. The Lewis score or the capsule endoscopy Crohn's disease activity index: which one is better for the assessment of small bowel inflammation in established Crohn's disease? *Therap Adv Gastroenterol* 2018; **11**: 1756283X17747780 [PMID: 29399042 DOI: 10.1177/1756283X17747780]

26 **Kopylov U**, Klang E, Yablecovitch D, Lahat A, Avidan B, Neuman S, Levhar N, Greener T, Rozendorn N, Beytelman A, Yanai H, Dotan I, Chowers Y, Weiss B, Ben-Horin S, Amitai MM, Eliakim R; Israeli IBD research Nucleus (IIRN). Magnetic resonance enterography versus capsule endoscopy activity indices for quantification of small bowel inflammation in Crohn's disease. *Therap Adv Gastroenterol* 2016; **9**: 655-663 [PMID: 27582877 DOI: 10.1177/1756283X16649143]

27 **He C**, Zhang J, Chen Z, Feng X, Luo Z, Wan T, Li A, Liu S, Ren Y. Relationships of capsule endoscopy Lewis score with clinical disease activity indices, C-reactive protein, and small bowel transit time in pediatric and adult patients with small bowel Crohn's disease. *Medicine (Baltimore)* 2017; **96**: e7780 [PMID: 28816962 DOI: 10.1097/MD.0000000000007780]

28 **Chong AK**, Taylor A, Miller A, Hennessy O, Connell W, Desmond P. Capsule endoscopy vs. push enteroscopy and enteroclysis in suspected small-bowel Crohn's disease. *Gastrointest Endosc* 2005; **61**: 255-261 [PMID: 15729235]

29 **Efthymiou A**, Viazis N, Vlachogiannakos J, Georgiadis D, Kalogeropoulos I, Mantzaris G, Karamanolis DG. Wireless capsule endoscopy versus enteroclysis in the diagnosis of small-bowel Crohn's disease. *Eur J Gastroenterol Hepatol* 2009; **21**: 866-871 [PMID: 19417679 DOI: 10.1097/MEG.0b013e32831af1ec]

30 **Carter D**, Katz LH, Bardan E, Salomon E, Goldstein S, Ben Horin S, Kopylov U, Eliakim R. The accuracy of intestinal ultrasound compared with small bowel capsule endoscopy in assessment of suspected Crohn's disease in patients with negative ileocolonoscopy. *Therap Adv Gastroenterol* 2018; **11**: 1756284818765908 [PMID: 29662538 DOI: 10.1177/1756284818765908]

31 **Petruzziello C**, Onali S, Calabrese E, Zorzi F, Ascolani M, Condino G, Lolli E, Naccarato P, Pallone F, Biancone L. Wireless capsule endoscopy and proximal small bowel lesions in Crohn's disease. *World J Gastroenterol* 2010; **16**: 3299-3304 [PMID: 20614486 DOI: 10.3748/wjg.v16.i26.3299]

32 **Sorrentino D**, Nguyen VQ. Clinically Significant Small Bowel Crohn's Disease Might Only be Detected by Capsule Endoscopy. *Inflamm Bowel Dis* 2018; **24**: 1566-1574 [PMID: 29893950 DOI: 10.1093/ibd/izy048]

33 **González-Suárez B**, Rodriguez S, Ricart E, Ordás I, Rimola J, Díaz-González Á, Romero C, de Miguel CR, Jáuregui A, Araujo IK, Ramirez A, Gallego M, Fernández-Esparrach G, Ginés Á, Sendino O, Llach J, Panés J. Comparison of Capsule Endoscopy and Magnetic Resonance Enterography for the Assessment of Small Bowel Lesions in Crohn's Disease. *Inflamm Bowel Dis* 2018; **24**: 775-780 [PMID: 29506048 DOI: 10.1093/ibd/izx107]

34 **Xavier S**, Cúrdia Gonçalves T, Dias de Castro F, Magalhães J, Rosa B, Moreira MJ, Cotter J. Perianal Crohn's disease - association with significant inflammatory activity in proximal small bowel segments. *Scand J Gastroenterol* 2018; **53**: 426-429 [PMID: 29447487 DOI: 10.1080/00365521.2018.1437928]

35 **Maunoury V**, Savoye G, Bourreille A, Bouhnik Y, Jarry M, Sacher-Huvelin S, Ben Soussan E, Lerebours E, Galmiche JP, Colombel JF. Value of wireless capsule endoscopy in patients with indeterminate colitis (inflammatory bowel disease type unclassified). *Inflamm Bowel Dis* 2007; **13**: 152-155 [PMID: 17206697 DOI: 10.1002/ibd.20060]

36 **Lopes S**, Figueiredo P, Portela F, Freire P, Almeida N, Lérias C, Gouveia H, Leitão MC. Capsule endoscopy in inflammatory bowel disease type unclassified and indeterminate colitis serologically negative. *Inflamm Bowel Dis* 2010; **16**: 1663-1668 [PMID: 20848457 DOI: 10.1002/ibd.21249]

37 **Long MD**, Barnes E, Isaacs K, Morgan D, Herfarth HH. Impact of capsule endoscopy on management of inflammatory bowel disease: a single tertiary care center experience. *Inflamm Bowel Dis* 2011; **17**: 1855-1862 [PMID: 21830264 DOI: 10.1002/ibd.21571]

38 **De Bona M**, Bellumat A, Cian E, Valiante F, Moschini A, De Boni M. Capsule endoscopy findings in patients with suspected Crohn's disease and biochemical markers of inflammation. *Dig Liver Dis* 2006; **38**: 331-335 [PMID: 16569524 DOI: 10.1016/j.dld.2006.02.004]

39 **Mehdizadeh S**, Chen GC, Barkodar L, Enayati PJ, Pirouz S, Yadegari M, Ippoliti A, Vasiliauskas EA, Lo SK, Papadakis KA. Capsule endoscopy in patients with Crohn's disease: diagnostic yield and safety. *Gastrointest Endosc* 2010; **71**: 121-127 [PMID: 19863957 DOI: 10.1016/j.gie.2009.06.034]

40 **Lorenzo-Zúñiga V**, de Vega VM, Domènech E, Cabré E, Mañosa M, Boix J. Impact of capsule endoscopy findings in the management of Crohn's Disease. *Dig Dis Sci* 2010; **55**: 411-414 [PMID: 19255845 DOI: 10.1007/s10620-009-0758-8]

41 **Urgesi R**, Cianci R, Marmo C, Costamagna G, Riccioni ME. But how many misunderstood Crohn's disease are revealed "by chance" using Capsule Endoscopy in Chronic Recurrent OGIB? Experience of a Single Italian Center and long term follow-up. *Eur Rev Med Pharmacol Sci* 2015; **19**: 4553-4557 [PMID: 26698252]

42 **Hall B**, Holleran G, Chin JL, Smith S, Ryan B, Mahmud N, McNamara D. A prospective 52 week mucosal healing assessment of small bowel Crohn's disease as detected by capsule endoscopy. *J Crohns Colitis* 2014; **8**: 1601-1609 [PMID: 25257546 DOI: 10.1016/j.crohns.2014.09.005]

43 **Shafran I,** Burgunder P, DePanicis R, Fitch K, Hewit S, Abbott L. Evaluation of mucosal healing in Small Bowel Crohn’s disease treated with Certolizumab Pegol assessed by wireless capsule endoscopy. *Clin Case Rep Rev* 2016; 2 [DOI: 10.15761/CCRR.1000284]

44 **Niv E**, Fishman S, Kachman H, Arnon R, Dotan I. Sequential capsule endoscopy of the small bowel for follow-up of patients with known Crohn's disease. *J Crohns Colitis* 2014; **8**: 1616-1623 [PMID: 24666976 DOI: 10.1016/j.crohns.2014.03.003]

45 **Kopylov U**, Yablecovitch D, Lahat A, Neuman S, Levhar N, Greener T, Klang E, Rozendorn N, Amitai MM, Ben-Horin S, Eliakim R. Detection of Small Bowel Mucosal Healing and Deep Remission in Patients With Known Small Bowel Crohn's Disease Using Biomarkers, Capsule Endoscopy, and Imaging. *Am J Gastroenterol* 2015; **110**: 1316-1323 [PMID: 26215531 DOI: 10.1038/ajg.2015.221]

46 **Aggarwal V**, Day AS, Connor S, Leach ST, Brown G, Singh R, Friedman A, Zekry A, Craig PI. Role of capsule endoscopy and fecal biomarkers in small-bowel Crohn's disease to assess remission and predict relapse. *Gastrointest Endosc* 2017; **86**: 1070-1078 [PMID: 28947363 DOI: 10.1016/j.gie.2017.09.011]

47 **Mitselos IV**, Katsanos KH, Tatsioni A, Skamnelos A, Eliakim R, Tsianos EV, Christodoulou DK. Association of clinical and inflammatory markers with small bowel capsule endoscopy findings in Crohn's disease. *Eur J Gastroenterol Hepatol* 2018; **30**: 861-867 [PMID: 29697457 DOI: 10.1097/MEG.0000000000001146]

48 **Rutgeerts P**, Geboes K, Vantrappen G, Beyls J, Kerremans R, Hiele M. Predictability of the postoperative course of Crohn's disease. *Gastroenterology* 1990; **99**: 956-963 [PMID: 2394349]

49 **Bourreille A**, Jarry M, D'Halluin PN, Ben-Soussan E, Maunoury V, Bulois P, Sacher-Huvelin S, Vahedy K, Lerebours E, Heresbach D, Bretagne JF, Colombel JF, Galmiche JP. Wireless capsule endoscopy versus ileocolonoscopy for the diagnosis of postoperative recurrence of Crohn's disease: a prospective study. *Gut* 2006; **55**: 978-983 [PMID: 16401689 DOI: 10.1136/gut.2005.081851]

50 **Biancone L**, Calabrese E, Petruzziello C, Onali S, Caruso A, Palmieri G, Sica GS, Pallone F. Wireless capsule endoscopy and small intestine contrast ultrasonography in recurrence of Crohn's disease. *Inflamm Bowel Dis* 2007; **13**: 1256-1265 [PMID: 17577246 DOI: 10.1002/ibd.20199]

51 **Pons Beltrán V**, Nos P, Bastida G, Beltrán B, Argüello L, Aguas M, Rubín A, Pertejo V, Sala T. Evaluation of postsurgical recurrence in Crohn's disease: a new indication for capsule endoscopy? *Gastrointest Endosc* 2007; **66**: 533-540 [PMID: 17725942 DOI: 10.1016/j.gie.2006.12.059]

52 **Kono T**, Hida N, Nogami K, Iimuro M, Ohda Y, Yokoyama Y, Kamikozuru K, Tozawa K, Kawai M, Ogawa T, Hori K, Ikeuchi H, Miwa H, Nakamura S, Matsumoto T. Prospective postsurgical capsule endoscopy in patients with Crohn's disease. *World J Gastrointest Endosc* 2014; **6**: 88-98 [PMID: 24634713 DOI: 10.4253/wjge.v6.i3.88]

53 **Hausmann J**, Schmelz R, Walldorf J, Filmann N, Zeuzem S, Albert JG. Pan-intestinal capsule endoscopy in patients with postoperative Crohn's disease: a pilot study. *Scand J Gastroenterol* 2017; **52**: 840-845 [PMID: 28431493 DOI: 10.1080/00365521.2017.1310289]

54 **Han ZM**, Qiao WG, Ai XY, Li AM, Chen ZY, Feng XC, Zhang J, Wan TM, Xu ZM, Bai Y, Li MS, Liu SD, Zhi FC. Impact of capsule endoscopy on prevention of postoperative recurrence of Crohn's disease. *Gastrointest Endosc* 2018; **87**: 1489-1498 [PMID: 29355520 DOI: 10.1016/j.gie.2018.01.017]

55 **Kusaka J**, Shiga H, Kuroha M, Kimura T, Kakuta Y, Endo K, Kinouchi Y, Shimosegawa T. Residual Lesions on Capsule Endoscopy Is Associated with Postoperative Clinical Recurrence in Patients with Crohn's Disease. *Dig Dis Sci* 2018; **63**: 768-774 [PMID: 29380174 DOI: 10.1007/s10620-018-4942-6]

56 **Levine A**, Griffiths A, Markowitz J, Wilson DC, Turner D, Russell RK, Fell J, Ruemmele FM, Walters T, Sherlock M, Dubinsky M, Hyams JS. Pediatric modification of the Montreal classification for inflammatory bowel disease: the Paris classification. *Inflamm Bowel Dis* 2011; **17**: 1314-1321 [PMID: 21560194 DOI: 10.1002/ibd.21493]

57 **Mao R**, Tang RH, Qiu Y, Chen BL, Guo J, Zhang SH, Li XH, Feng R, He Y, Li ZP, Zeng ZR, Eliakim R, Ben-Horin S, Chen MH. Different clinical outcomes in Crohn's disease patients with esophagogastroduodenal, jejunal, and proximal ileal disease involvement: is L4 truly a single phenotype? *Therap Adv Gastroenterol* 2018; **11**: 1756284818777938 [PMID: 29899757 DOI: 10.1177/1756284818777938]

58 **Gionchetti P**, Dignass A, Danese S, Magro Dias FJ, Rogler G, Lakatos PL, Adamina M, Ardizzone S, Buskens CJ, Sebastian S, Laureti S, Sampietro GM, Vucelic B, van der Woude CJ, Barreiro-de Acosta M, Maaser C, Portela F, Vavricka SR, Gomollón F; ECCO. 3rd European Evidence-based Consensus on the Diagnosis and Management of Crohn's Disease 2016: Part 2: Surgical Management and Special Situations. *J Crohns Colitis* 2017; **11**: 135-149 [PMID: 27660342 DOI: 10.1093/ecco-jcc/jjw169]

59 **Leenhardt R,** Li C, Koulaouzidis A, Cavallaro F, Cholet F, Eliakim AR, Fernandez-Urien I, Kopylov U, McAlindon M, Nemeth A, Plevris JN, Rahmi G, Rondonotti E, Saurin J-C, Tontini GE, Toth E, Yung DE, Marteau PR, Dray X. Sa1028 Terminology And Description Of Vascular Lesions In Small Bowel Capsule Endoscopy: An International Delphi Consensus Statement. *Gastrointest Endosc* 2018; **87**: AB149–150 [DOI: 10.1016/j.gie.2018.04.1379]

60 **Jensen MD**, Brodersen JB, Kjeldsen J. Capsule endoscopy for the diagnosis and follow up of Crohn's disease: a comprehensive review of current status. *Ann Gastroenterol* 2017; **30**: 168-178 [PMID: 28243037 DOI: 10.20524/aog.2016.0119]

61 **Rokkas T**, Papaxoinis K, Triantafyllou K, Pistiolas D, Ladas SD. Does purgative preparation influence the diagnostic yield of small bowel video capsule endoscopy?: A meta-analysis. *Am J Gastroenterol* 2009; **104**: 219-227 [PMID: 19098872 DOI: 10.1038/ajg.2008.63]

62 **Koulaouzidis A**, Giannakou A, Yung DE, Dabos KJ, Plevris JN. Do prokinetics influence the completion rate in small-bowel capsule endoscopy? A systematic review and meta-analysis. *Curr Med Res Opin* 2013; **29**: 1171-1185 [PMID: 23790243 DOI: 10.1185/03007995.2013.818532]

63 **Kotwal VS**, Attar BM, Gupta S, Agarwal R. Should bowel preparation, antifoaming agents, or prokinetics be used before video capsule endoscopy? A systematic review and meta-analysis. *Eur J Gastroenterol Hepatol* 2014; **26**: 137-145 [PMID: 24220156 DOI: 10.1097/MEG.0b013e328365b9d4]

64 **Yung DE**, Rondonotti E, Sykes C, Pennazio M, Plevris JN, Koulaouzidis A. Systematic review and meta-analysis: is bowel preparation still necessary in small bowel capsule endoscopy? *Expert Rev Gastroenterol Hepatol* 2017; **11**: 979-993 [PMID: 28737439 DOI: 10.1080/17474124.2017.1359540]

65 **Wu L**, Cao Y, Liao C, Huang J, Gao F. Systematic review and meta-analysis of randomized controlled trials of Simethicone for gastrointestinal endoscopic visibility. *Scand J Gastroenterol* 2011; **46**: 227-235 [PMID: 20977386 DOI: 10.3109/00365521.2010.525714]

66 **Klein A**, Dashkovsky M, Gralnek I, Peled R, Chowers Y, Khamaysi I, Har-Noy O, Levi I, Nadler M, Eliakim R, Kopylov U. Bowel preparation in "real-life" small bowel capsule endoscopy: a two-center experience. *Ann Gastroenterol* 2016; **29**: 196-200 [PMID: 27064840 DOI: 10.20524/aog.2016.0012]

67 **Nakamura M**, Murino A, O'Rourke A, Fraser C. A critical analysis of the effect of view mode and frame rate on reading time and lesion detection during capsule endoscopy. *Dig Dis Sci* 2015; **60**: 1743-1747 [PMID: 25559755 DOI: 10.1007/s10620-014-3496-5]

68 **Günther U**, Daum S, Zeitz M, Bojarski C. Capsule endoscopy: comparison of two different reading modes. *Int J Colorectal Dis* 2012; **27**: 521-525 [PMID: 22065113 DOI: 10.1007/s00384-011-1347-9]

69 **Shiotani A**, Honda K, Kawakami M, Kimura Y, Yamanaka Y, Fujita M, Matsumoto H, Tarumi K, Manabe N, Haruma K. Analysis of small-bowel capsule endoscopy reading by using Quickview mode: training assistants for reading may produce a high diagnostic yield and save time for physicians. *J Clin Gastroenterol* 2012; **46**: e92-e95 [PMID: 22495816 DOI: 10.1097/MCG.0b013e31824fff94]

70 **Koulaouzidis A**, Smirnidis A, Douglas S, Plevris JN. QuickView in small-bowel capsule endoscopy is useful in certain clinical settings, but QuickView with Blue Mode is of no additional benefit. *Eur J Gastroenterol Hepatol* 2012; **24**: 1099-1104 [PMID: 22668872 DOI: 10.1097/MEG.0b013e32835563ab]

71 **Halling ML**, Nathan T, Kjeldsen J, Jensen MD. High sensitivity of quick view capsule endoscopy for detection of small bowel Crohn's disease. *J Gastroenterol Hepatol* 2014; **29**: 992-996 [PMID: 24325204 DOI: 10.1111/jgh.12488]

72 **Pennazio M**, Spada C, Eliakim R, Keuchel M, May A, Mulder CJ, Rondonotti E, Adler SN, Albert J, Baltes P, Barbaro F, Cellier C, Charton JP, Delvaux M, Despott EJ, Domagk D, Klein A, McAlindon M, Rosa B, Rowse G, Sanders DS, Saurin JC, Sidhu R, Dumonceau JM, Hassan C, Gralnek IM. Small-bowel capsule endoscopy and device-assisted enteroscopy for diagnosis and treatment of small-bowel disorders: European Society of Gastrointestinal Endoscopy (ESGE) Clinical Guideline. *Endoscopy* 2015; **47**: 352-376 [PMID: 25826168 DOI: 10.1055/s-0034-1391855]

73 **Goldfarb NI**, Pizzi LT, Fuhr JP Jr, Salvador C, Sikirica V, Kornbluth A, Lewis B. Diagnosing Crohn's disease: an economic analysis comparing wireless capsule endoscopy with traditional diagnostic procedures. *Dis Manag* 2004; **7**: 292-304 [PMID: 15671786 DOI: 10.1089/dis.2004.7.292]

74 **Leighton JA**, Gralnek IM, Richner RE, Lacey MJ, Papatheofanis FJ. Capsule endoscopy in suspected small bowel Crohn's disease: economic impact of disease diagnosis and treatment. *World J Gastroenterol* 2009; **15**: 5685-5692 [PMID: 19960565 DOI: 10.3748/wjg.15.5685]

75 **Herrerias JM**, Leighton JA, Costamagna G, Infantolino A, Eliakim R, Fischer D, Rubin DT, Manten HD, Scapa E, Morgan DR, Bergwerk AJ, Koslowsky B, Adler SN. Agile patency system eliminates risk of capsule retention in patients with known intestinal strictures who undergo capsule endoscopy. *Gastrointest Endosc* 2008; **67**: 902-909 [PMID: 18355824 DOI: 10.1016/j.gie.2007.10.063]

76 **Kopylov U**, Nemeth A, Cebrian A, Wurm Johansson G, Thorlacius H, Fernandez-Urien Sainz I, Koulaouzidis A, Eliakim R, Toth E. Symptomatic retention of the patency capsule: a multicenter real life case series. *Endosc Int Open* 2016; **4**: E964-E969 [PMID: 27652302 DOI: 10.1055/s-0042-112588]

77 **Leighton JA**, Helper DJ, Gralnek IM, Dotan I, Fernandez-Urien I, Lahat A, Malik P, Mullin GE, Rosa B. Comparing diagnostic yield of a novel pan-enteric video capsule endoscope with ileocolonoscopy in patients with active Crohn's disease: a feasibility study. *Gastrointest Endosc* 2017; **85**: 196-205.e1 [PMID: 27658907 DOI: 10.1016/j.gie.2016.09.009]

78 **Tukey M**, Pleskow D, Legnani P, Cheifetz AS, Moss AC. The utility of capsule endoscopy in patients with suspected Crohn's disease. *Am J Gastroenterol* 2009; **104**: 2734-2739 [PMID: 19584828 DOI: 10.1038/ajg.2009.404]

79 **Dussault C**, Gower-Rousseau C, Salleron J, Vernier-Massouille G, Branche J, Colombel JF, Maunoury V. Small bowel capsule endoscopy for management of Crohn's disease: a retrospective tertiary care centre experience. *Dig Liver Dis* 2013; **45**: 558-561 [PMID: 23238033 DOI: 10.1016/j.dld.2012.11.004]

80 **Kalla R**, McAlindon ME, Drew K, Sidhu R. Clinical utility of capsule endoscopy in patients with Crohn's disease and inflammatory bowel disease unclassified. *Eur J Gastroenterol Hepatol* 2013; **25**: 706-713 [PMID: 23325280 DOI: 10.1097/MEG.0b013e32835ddb85]

81 **Flamant M**, Trang C, Maillard O, Sacher-Huvelin S, Le Rhun M, Galmiche JP, Bourreille A. The prevalence and outcome of jejunal lesions visualized by small bowel capsule endoscopy in Crohn's disease. *Inflamm Bowel Dis* 2013; **19**: 1390-1396 [PMID: 23552764 DOI: 10.1097/MIB.0b013e31828133c1]

82 **Cotter J**, Dias de Castro F, Moreira MJ, Rosa B. Tailoring Crohn's disease treatment: the impact of small bowel capsule endoscopy. *J Crohns Colitis* 2014; **8**: 1610-1615 [PMID: 24631311 DOI: 10.1016/j.crohns.2014.02.018]

83 **Chao CY**, Duchatellier CF, Seidman EG. Unsuspected Small-Bowel Crohn's Disease in Elderly Patients Diagnosed by Video Capsule Endoscopy. *Diagn Ther Endosc* 2018; **2018**: 9416483 [PMID: 29622900 DOI: 10.1155/2018/9416483]

84 **Hansel SL**, McCurdy JD, Barlow JM, Fidler J, Fletcher JG, Becker B, Prabhu NC, Faubion WA, Hanson KA, Kane SV, Kisiel JB, Loftus EV Jr, Papadakis KA, Pardi DS, Raffals LE, Schoenoff S, Tremaine WJ, Bruining DH. Clinical Benefit of Capsule Endoscopy in Crohn's Disease: Impact on Patient Management and Prevalence of Proximal Small Bowel Involvement. *Inflamm Bowel Dis* 2018; **24**: 1582-1588 [PMID: 29788055 DOI: 10.1093/ibd/izy050]

85 **Efthymiou A**, Viazis N, Mantzaris G, Papadimitriou N, Tzourmakliotis D, Raptis S, Karamanolis DG. Does clinical response correlate with mucosal healing in patients with Crohn's disease of the small bowel? A prospective, case-series study using wireless capsule endoscopy. *Inflamm Bowel Dis* 2008; **14**: 1542-1547 [PMID: 18521929 DOI: 10.1002/ibd.20509]

86 **Tsibouris P**, Periklis A, Chrissostomos K, Antonios Z, Panagiota M, Erasmia V, Georgios A. When Crohn's disease is in remission, more patients complete capsule endoscopy study but less lesions are identified. *Saudi J Gastroenterol* 2013; **19**: 63-68 [PMID: 23481131 DOI: 10.4103/1319-3767.108468]

87 **Nakamura M**, Yamamura T, Maeda K, Sawada T, Mizutani Y, Ishikawa T, Furukawa K, Ohno E, Kawashima H, Miyahara R, Koulaouzidis A, Hirooka Y; Nagoya University Crohn’s Disease Study Group. Validity of Capsule Endoscopy in Monitoring Therapeutic Interventions in Patients with Crohn's Disease. *J Clin Med* 2018; **7**: [PMID: 30274238 DOI: 10.3390/jcm7100311]

**P-Reviewer:** Abdolghaffari AH, Day AS, Mattar MC **S-Editor:** Ma YJ **L-Editor: A E-Editor:** Ma YJ

**Specialty type:** Gastroenterology and hepatology

**Country of origin:** France

**Peer-review report classification**

Grade A (Excellent): A, A

Grade B (Very good): B

Grade C (Good): 0

Grade D (Fair): 0

Grade E (Poor): 0

**Table 1 Studies showing the impact of small bowel capsule endoscopy on disease reclassification and subsequent patient management during follow-up of patients suspected or diagnosed with inflammatory bowel disease**

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| **Ref.** | **Study design** | **Sample size** | **Patient population** | **Compared modality** | **CE lesions considered diagnostic for CD** | **Positive SB findings** | **Impact in patient management1** |
| Reclassification of Crohn’s disease location | | | | | | | |
| Chong *et al*[28], 2005 | Prospective, blinded | 43 | Group 1:  Known CD  (*n =* 22)  Group 2:  Suspected CD2 (*n =* 21) | Push enteroscopy and enteroclysis | ≥ 1 erosion/  ulcer | Group 1: 17/22 (jejunum, *n =* 7) *vs* 3/22 at push enteroscopy, *P <* 0.001 and 4/21 at enteroclysis, *P <* 0.001  Group 2: 4/21 (jejunum, *n =* 2), no statistically significant difference *vs* other modalities | 30/43 (70%)  Group 1: 16 (73%)  Group 2: 14 (67%) |
| De Bona *et al*[38], 2006 | Prospective | 38 | Suspected CD2  Group 1: Ongoing symptoms (*n =* 12)  Group 2: Ongoing symptoms and inflammatory biomarkers3 (*n =* 26) | NA | Diagnostic if > 3 erosions/  ulcerations  Suspicious if ≤ 3 and/or  nodular pattern | Diagnostic: 13/38 (34.2%)  (jejunum, *n =* 5)  Suspicious: 2/38 (5.3%)  Group 1: 1/12 (8.3%)  Group 2: 14/26 (46.2%)  *P =* 0.022 | 15/38 (39.5%) *i.e.,* 100% of patients with positive CE findings |
| Efthymiou *et al*[29], 2009 | Prospective, blinded | 55 | Group 1:  Known CD (*n =* 29)  Group 2: Suspected CD2 (*n =* 26) | Enteroclysis | Diffuse erythema, erosions, > 3 aphthoid  ulcers, ulcers of different shape  and strictures | Group 1: 20/29 (jejunum, *n =* 8) *vs* 11/27 at enteroclysis4, incremental diagnostic yield= 33.4% (*P =* 0.035)  Group 2: 16/26 (jejunum, *n =* 6), *vs* 6/20 at enteroclysis5, incremental diagnostic yield = 35.0% (*P =* 0.039) | - |
| Tukey *et al*[78], 2009 | Retrospective | 105 | Suspected CD2 | NA | Any ulcers | 39/105 (37%)  Prevalence rate of CD diagnosis after a 12-mo follow-up *=* 13%  Se 77%, Sp 89%, PPV 50%, NPV 96% | - |
| Mehdizadeh *et al*[39], 2010 | Retrospective | 134 | Known CD | NA | Diagnostic if > 3  ulcerations  Suspicious if ≤ 3 ulcerations | Diagnostic: 52/134 (38.8%)  Suspicious: 17/134 (12.7%)  Jejunum lesions 53%,  proximal ileum lesions 67% | 52/134 (38.8%) *i.e.,* 100% of patients with positive CE findings |
| Lorenzo-Zúñiga *et al*[40], 2010 | Retrospective | 14 | Known CD | NA | ≥ 7 mucosal breaks or ulcerations | 12/14 (86%)  According to indications of CE:  Abdominal pain=3/3  Anemia = 5/5  Disease extent re-evaluatio*n =* 4/6 | 9/14 (64%) *i.e.,* 100% of patients in whom CE was performed because of abdominal  pain, 80% for anemia, 33% for  disease extent re-evaluation |
| Petruzziello *et al*[31], 2010 | Prospective | 64 | Known CD of the distal ileum (*n =* 32)  Control group (*n =* 32) | SICUS | > 3 aphthoid ulcers, deep ulcers, stricture(s) | CD group: 16/32 (50%) with upper SB lesions *vs* 3/32 (9%) at SICUS, 30/32 (93%) with distal SB lesions *vs* 30/32 (93%) at SICUS  Control group: 0/32 (0%) | - |
| Dussault *et al*[79], 2013 | Retrospective | 71 | Known CD | NA | Moderate: erythema  and few aphthoid ulcers  Severe: multiple and/or deep ulcers  and/or stenosis | Moderate: 32/71 (45.1%)  Severe: 12 (16.9%)  According to indications of CE:  Anemia = 4/6  Symptoms = 11/25  Disease re-evaluatio*n =* 28/37 | 38/71 (53.5%) *i.e.,* 75% of patients with severe lesions and 53% with moderate lesions |
| Kalla *et al*[80], 2013 | Retrospective | 315 | Known (*n =* 50) or suspected2 (*n =* 265) CD | NA | > 3 ulcers with erythema or edema | Known CD: 33/50 (66%) (jejunum, *n =* 1 / diffuse, *n =* 16)  Suspected CD: 45/265 (17%) (jejunum, *n =* 5 / diffuse, *n =* 7) | Known CD: 73%  Suspected CD: 90%  of patients with positive CE findings |
| Flamant *et al*[81], 2013 | Retrospective | 108 | Known CD  (32 L1, 25 L2, 51 L3) | NA | Diffuse erythema and edema, linear/  circumferential ulcerations, ≥ 3 aphthous  ulcers, or stenosis | 68/108 (63%) (jejunum, *n =* 60 of whom *n =* 18 *i.e.,* 17% only in the jejunum)  Restricted colonic location of the disease associated with  a significantly decreased risk of jejunal lesions by 80% (OR *=* 0.21, *P =* 0.002) | -  Jejunal lesions=sole independent factor associated  with increased risk of clinical relapse (HR = 1.99, *P =* 0.02) |
| Cotter *et al*[82], 2014 | Retrospective | 50 | Known CD | NA | Moderate:  Lewis score ≥ 135  Severe:  Lewis score > 790 | Moderate:  33/50 (66%)  Severe:  11/50 (22%) | Proportion of patients on thiopurines and/or biologics increasing from 2/50 (4%) to 15/50 (30%) after CE, *P =* 0.023 |
| Urgesi *et al*[41], 2015 | Retrospective | 492 | Suspected CD on obscure gastrointestinal bleeding | NA | Mucosal fissure, ulcers of different shape, cobblestoning mucosa,  aphthous ulcers,  stricture(s), erythema/edema, loss of villi | 94/492 (19.1%) (jejunum, *n =* 31) | 64/94 -68%) *i.e.,* 100% of confirmed CD |
| Greener *et al*[10], 2016 | Prospective | 79 | Known CD | MRE | Lewis score ≥ 135 | Proximal disease location detected by CE in 51% of patients *vs* 26% by MRE (*P <* 0.01) (isolated proximal lesions, *n =* 9) | - |
| Chao *et al*[83], 2018 | Retrospective | 197 | Suspected CD in elderly patients2 | NA | Lewis score > 790 | 8/197 (4.1%) | 4/197 (2.0%) *i.e.,* 50% of patients with positive CD findings |
| Carter *et al*[30], 2018 | Prospective, blinded | 50 | Suspected CD2 | Intestinal ultrasound | Lewis score ≥ 135 | Similar diagnostic yield: 19/50 (38%) for SBCE and intestinal ultrasound, correlation *r =* 0.532, *P <* 0.001 | - |
| Sorrentino and Nguyen[32], 2018 | Retrospective | 43 | Known CD (20 never had surgery, 23 in the post-operative setting) | Ileocolono-scopy and MRE/CTE and CRP/FL | Any ulcerations or multiple erosions | Surgery-naïve group: 13/20 (65%) *vs* 8/20 (40%) at ileocolonoscopy *vs* 9/206 (45%) at imaging *vs* 12/207 (60%) at biomarkers  Post-operative group: 20/23 (87%) *vs* 16/238 (70%) at ileocolonoscopy *vs* 0/239 (0%) at imaging *vs* 13/23 (57%) at biomarkers | Surgery-naïve group: 6/20 (30%)  Post-operative group: 12/23 (52%) |
| Hansel *et al*[84], 2018 | Prospective | 50 | Known CD with normal imaging | NA | Diffuse erythema and edema, linear or circumferential  ulceration(s), ≥ 3 aphthous ulcers,  or stenosis | 14/50 (28%) with proximal SB lesions (duodenum, jejunum) | 17/50 (34%) |
| González-Suárez *et al*[33], 2018 | Retrospective | 47 | Known CD (*n =* 32) or suspected (*n =* 15) CD | MRE | Lewis score ≥ 135 | 36/47 (76.6%) *vs* 21/47 (44.7%) at MRE, *P =* 0.001, of which jejunal lesions: 15/47 (31.9%) *vs* 3/47 (6.4%), *P =* 0.02 | - |
| Xavier *et al*[34], 2018 | Retrospective | 71 | Perianal CD (*n =* 17) and non-perianal CD (*n =* 54) | NA | Villous edema, erosions, ulcers or stenosis | Perianal CD: 94.1% *vs* 66.6% in non-perianal CD (*P =* 0.03), with more frequently a Lewis Score ≥ 135: 94.1% *vs* 64.8% (*P =* 0.03), and higher Lewis scores in the first and second tertiles but not in the third tertile | - |
| Reclassification of inflammatory bowel disease type | | | | | | | |
| Maunoury *et al*[35], 2007 | Prospective | 30 | IBD-U with negative ASCA/ANCA and normal SBFT | NA | ≥3 ulcerations | 5/30 (16.7%) (jejunum, *n =* 4) | - |
| Lopes *et al*[36], 2010 | Prospective | 18 | IBD-U (*n =* 14) or IC (*n =* 4) with negative ASCA/ANCA | NA | Diagnostic if ≥ 4 erosions/ulcers and/or stricture(s)  Suspicious if < 4 and/or focal  villi denudation | Diagnostic: 7/18 (38.9%)  Suspicious: 9/18 (50.0%)  Jejunum and proximal ileum lesions: 8/18 (44.4%) | 0 (0%) |
| Long *et al*[37], 2011 | Retrospective | 124 | CD (*n =* 86) or IC (*n =* 15) or pouchitis (*n =* 23) | NA | Erythema, few aphthae/ulcers, multiple aphthae/ulcers, stenosis | CD: 67/86 (77.9%)  IC: 7/15 (46.7%)  Pouchitis: 15/23 (65.2%) | Medication:  CD: 34/86 (39.5%)  IC: 6/15 (40.0%)  Pouchitis: 13/23 (56.5%)  Surgery:  CD: 11/86 (12.8%)  IC: 6/15 (40.0%)  Pouchitis: 1/23 (4.4%) |

1Change in the dose or change of immunomodulatory agent, or initiation of biologic treatment, or avoidance of surgery; 2Ongoing symptoms or iron deficiency anemia despite negative upper/lower endoscopy and/or small bowel follow-through and/or abdominal computed tomography scan; 3Increased C-reactive protein and/or erythrocyte sedimentation rate; 4Enteroclysis was unsuccessful in two patients; 5Enteroclysis was unsuccessful in six patients; 6Imaging (CTE or MRE) was not performed in 5 patients; 7Fecal lactoferrin and CRP were not performed in 1 patient; 8Ileocolonoscopy was not performed in 1 patient; 9Imaging (CTE or MRE) was not performed in 15 patients. ANCA: Anti-neutrophil cytoplasmic antibodies ; ASCA: Anti-Saccharomyces cerevisiae antibodies ; CD: Crohn’s disease; CE: Capsule endoscopy; CRP: C-reactive protein; CTE: Computed tomography enterography; FL: Fecal lactoferrin; IBD: Inflammatory bowel disease; IC: Indeterminate colitis; MRE: Magnetic resonance enterography; NA: Not applicable; NPV: Negative predictive value; OR: Odds ratio; PPV: Positive predictive value; SB: Small bowel; SBFT: Small bowel follow-through; Se: Sensivity; SICUS: Small intestine contrast ultrasonography; Sp: Specificity.

**Table 2 Studies evaluating the use of small bowel capsule endoscopy in the assessment of mucosal healing in patients diagnosed with Crohn’s disease**

|  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Ref.** | **Study design** | **Sample size** | **Treatment evaluated** | **Prior biologic exposure** | **Interval between the CE** | **CE findings considered for assessing mucosal healing** | **Positive SB findings before treatment** | **Positive SB findings after treatment** | ***P*-value** |
| Efthymiou *et al*[85], 2008 | Prospective, blinded | 40 | CS (60%)  Mesalamine (70%)  Azathioprine (10%)  Infliximab (5%)  Metronidazole (20%) | - | After achievement of clinical remission:  4 wk (75%)  6 wk (15%)  8 wk (10%) | Number of apthous ulcers, mean ± SE  Number of large ulcers, mean ± SE  Percentage of the SBTT in which any endoscopic lesion was visible, mean ± SE | 26.0 ± 7.5  8.3 ± 1.4  22.0 ± 3.1 | 12.7 ± 2.3  5.0 ± 0.8  17.8 ± 2.5 | 0.07  **0.01**  0.08 |
| Tsibouris *et al*[86], 2013 | Prospective, blinded | 1021 | - | - | ≥ 15 d after CDAI dropped  < 150:  2-3 mo. (26.5%)  3-6 mo. (19.6%)  6-12 mo. (53.9%) | CECDAI score, mean ± SD | 14 ± 6 | 4 ± 2 | - |
| Niv *et al*[44], 2014 | Prospective, blinded | 19 | Copaxone (68.4%)  5-ASA (52.6%)  Antibiotics (15.8%)  CS (5.3%)  IS (10.5%)  Vitamins (26.3%)  Others (36.8%) | - | 12 wk | Lewis score, mean ± SD | 1730 ± 1780 | No correlation between changes in CDAI/IBDQ and Lewis score2 | - |
| Hall *et al*[42], 2014 | Prospective, blinded | 43 | Adalimumab (84%)  160 mg W0, 80 mg W2, then 40 mg /2 wk  or  Azathioprine (16%) 2-2.5 mg/kg | Naïve  38/43  Exposed  5/43 | 52 wk3 | Complete MH = Absence of ulcers, *n* (%)  Normalization of CECDAI score < 3.5, *n* (%)  Change in CECDAI score, *n* (%) | -  -  CECDAI<3.5:  4/43 (9%)  3.5 ≤ CECDAI < 5.8:  13/43 (30%)  CECDAI ≥ 5.8:  26/43 (61%) | Complete MH: 12/28 (43%)  CECDAI < 3.5:  2/28 (7%)  CECDAI ≤ 3.5 < 5.8:  6/28 (21%)  CECDAI ≥ 5.8:  8/28 (29%) | **< 0.0001** |
| Kopylov *et al*[45], 2015 | Prospective | 52 | None (15.4%)  5-ASA (9.6%)  Thiopurine (36.6%)  Anti-TNF (26.9%) Anti-TNF+IS (11.5%) | - | NA  Included patients were all in clinical remission (CDAI < 150) and had only one CE. | MH = Lewis score < 135 | NA | MH:  8/52 (15.4%)  135 ≤ Lewis < 790:  33/52 (63.5%)  Lewis score ≥ 790:  11/52 (21.2%) | **-** |
| Shafran *et al*[43], 2016 | Prospective, open-label | 15 | Certolizumab pegol 400 mg W0, W2, W4 then /4 wk | Naïve 3/15  Exposed 12/154 | 24 wk in responders | Lewis score, mean | 1663 | 226 | - |
| Aggarwal *et al*[46], 2017 | Prospective, blinded | 43 | None (14%)  5-ASA (60%)  CS (12%)  IS (74%)  Anti-TNF (21%) | - | NA  Included patients were all in clinical remission (CDAI < 150) and had only one CE. | MH = Lewis score < 135 | NA | MH:  17/43 (40%)  135 ≤ Lewis < 790:  19/43 (44%)  Lewis score ≥ 790:  7/43 (16%)  Significant correlation between Lewis score and fecal calprotectin (*r =* 0.82, *P <* **0.0001**) | - |
| Mitselos *et al*[47], 2018 | Retrospective | 30 | None (37%)  5-ASA (17%)  Budesonide (10%)  Azathioprine (10%)  Anti-TNF (20%)  Anti-TNF+IS (6%) | - | NA  Included patients had only one CE (60% in both clinical and biochemical remission) | MH = Lewis score < 1355 | NA | MH:  6/15 (40%)  Weak correlation  between CDAI and Lewis score (*r =* 0.32, *P =* 0.088) and between CRP and Lewis score  (*r =*  0.52, *P =* **0.004**) | - |
| Nakamura *et al*[87], 2018 | Prospective, blinded | 92 | None (27%)  5-ASA (18%)  Thiopurines (17%)  Infliximab (20%);  Adalimumab (10%)  Elemental diet (5%)  CS (3%) | Naïve  38/92 Exposed  54/92 | 6 mo in the active group (40/92)  Non-active patients ended the study at baseline (52/92) | Lewis score, mean  MH = Lewis score of 0  Active CD: Lewis score > 135 | 458 | 233  MH:  2/296  Improvement of LS in all 7 patients who received biologics, and in 8/11 (73%) of asymptomatic patients receiving additional medication | **0.0004** |

1Eighteen percent of patients had Crohn’s disease restricted to the colon; 2Nine patients did not have CE at week 12; 3Fifteen patients did not have CE at week 52; 4Two patients had an allergic reaction to infliximab, 10 patients were secondary non-responders to infliximab and/or adalimumab; 5Data presented for patients in both clinical and biochemical remission (CDAI<150 and CR*P <* 5 mg/L); 6Of 40 patients in the active group, 29 (72%) underwent follow-up CE to assess the therapeutic effect on MH. ASA: Aminosalicylic acid; CD: Crohn’s disease; CE: Capsule endoscopy; CECDAI: Capsule EndoscopyCrohn's Disease Activity Index; CS: Corticosteroids; IS: Immunosuppressant; LS: Lewis score; MH: Mucosal healing; SB: Small bowel; SBTT: Small bowel transit time.

**Table 3 Studies assessing the use of small bowel capsule endoscopy in the monitoring of patients with Crohn’s disease in the post-operative setting**

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Reference** | **Study design** | **Sample size** | **Indication for surgery** | **Risk factors for POR** | **Post-operative prophylactic treatment** | **Compared modality** | **Interval between surgery and endoscopic re-assessment** | **CE findings considered for defining POR** | **Rate of clinical recurrence, *n* (%)** | **Rate of endoscopic recurrence,**  ***s* (%)** |
| Bourreille *et al*[49], 2006 | Prospective, blinded | 32 | Resistance to medical treatment (19%)  Stenosis (37%)  Fistula/abscess (44%) | - | None (28%)  5-ASA (22%)  CS (3%)  IS (9%)  Others (44%) | Ileocolono-scopy | Median (IQR):  6 mo. (4-7) | Rutgeerts score ≥i,1 | - | Colonoscopy:  19/311 (61%)  Se 90%, Sp 100%  WCE:  21/31 (68%)  Se 76%, Sp 91%  SB lesions up to 72% |
| Biancone *et al*[50], 2007 | Prospective, blinded | 22 | Resistance to medical treatment (9%)  Stenosis (64%)  Fistula/abscess (14%)  Other (13%) | Smoking (32%)  Penetrating phenotype (23%) | Mesalamine (100%) | Ileocolono-scopy (gold standard),  SICUS | 1 year | Ulcers,  strictures, or stenosis in the neoterminal ileum and/or anastomosis | 0 (0%) | Ileocolonoscopy:  16/172 (94%)  SICUS:  17/172 (1 FP) (100%)  WCE:  16/172 (94%)  Se 93%, Sp 67% |
| Pons Beltrán *et al*[51], 2007 | Prospective, blinded | 24 | Resistance to medical treatment (21%)  Stenosis (63%)  Other (16%) | Smoking (50%)  Penetrating phenotype (38%) | None (100%) | Ileocolono-scopy | Median (range): 254 d  (118-439) | Rutgeerts score ≥i,2 | 0 (0%) | Ileocolonoscopy:  6/24 (25%)  WCE:  15/24 (63%)  Jejunal lesions (54%) |
| Kono *et al*[52], 2014 | Prospective, blinded | 19 | - | Smoking (11%)  Penetrating phenotype (58%)  Prior resection (68%) | 5-ASA (39%)  Anti-TNF (61%) | Ileocolono-scopy at 6-8 mo. | mean ± SD:  17.3 ± 5.6 d  then  216.9 ± 23.6 d | Lewis score ≥ 135, *n* (%)  and  Mean (range) | 0 (0%) | Week 2-3:  14/183 (78%)  428.3 (8-4264)  6-8 mo.:  9/134 (69%) *vs* 3/6 (50%) at colonoscopy  196.1 (8-450)  5/13 (38%) with LS higher by ≥ 100 than shortly after surgery |
| Hausmann *et al*[53], 20175 | Prospective, blinded | 22 | - | Penetrating phenotype (18%)  Prior resection (50%) | None (76%)  Azathioprine (6%)  Adalimumab (18%) | Ileocolono-scopy at 4-8 mo. | Mean (range):  57.5 (34–83) d  then  220 (159–322) d | Modified Rutgeerts score ≥i,2 | - | Week 4-8:  3/166 (19%)  4-8 mo.: 7  6/12 (50%) *vs* 5/15 (33%) at colonoscopy |
| Han *et al*[54], 2018 | Retrospective, blinded | 83 | Resistance to medical treatment (24.3%)  Stenosis (75.7%) | None (100%) | None (100%) before date 1  After date 1 if POR:  None (53.1%)  Azathioprine (21.6%) Infliximab  (25.3%) | Group 1 (37/83): ileocolono-scopy + CE (date 1) then repeat colonoscopy (date 2)  Group 2  (46/83):  ileocolono-scopy (date 1 and 2) | Date 1:  3-7 mo. after surgery  Date 2:  1 year after date 1 | Rutgeerts score ≥i,2 in the terminal ileum  or >5 aphthous lesions in proximal SB  or ulcers in proximal SB | Group 1:  1/37 (2.7%)  Group 2:  10/46 (21.7%)  *P =* **0.019** | Date 1:  Group 1: 13/37 (35.1%) at IC *vs* 24/37 (64.9%) at CE  Group 2: 15/46 (32.6%) at IC  (*P =* 0.809)  Date 2:  Group 1: 8/37 (21.6%)  Group 2: 20/46 (43.5%)  (*P =* **0.036**) |
| Kusaka *et al*[55], 2018 | Prospective | 25 | - | Smoking (22%)  Penetrating phenotype (7%)  Prior resection (48%) | 5-ASA (96%)  Elemental diet (30%)  IS (19%)  Anti-TNF (59%)8 | - | < 3 mo | Lewis score ≥135 | 5/25 (20%) | 21/25 (84%)  mean ± SD:  751.3 ± 984.0  Clinical recurrence rate significantly higher in the group with  highest third tertile score (distal SB) |

1The neoterminal ileum was reached and explored by ileocolonoscopy in 31 patients; 2WCE was not performed because of luminal narrowing or stenosis in 5 patients, thus 17 of the 22 patients had all 3 techniques performed; 3In one patient CE did not reach beyond the middle segment of the ileum during the 8 h of recording; 4The follow-up CE at 6-8 mo. after surgery was possible in 13 of the 18 patients; 5Study assessing the use of pan-intestinal capsule endoscopy (PICE); 6Seventeen of the 22 patients (77%) underwent CE at 4-8 wk. Another CE could not be analyzed due to an insufficient large bowel preparation; 7Of 17 patients included in the study at follow-up, 14 (82%) underwent CE, and in two cases, analysis of CE videos was hampered by a technical defect and an insufficient large bowel preparation, and 15 (88%) underwent ileocolonoscopy; 8Patients could have more than one treatment. ASA: Aminosalicylic acid; CE: Capsule endoscopy; CS: Corticosteroids; FP: False positive; IC: Ileocolonoscopy; IQR: Interquartile range; IS: Immunosuppressant; POR: Post-operative recurrence; SB: Small bowel; Se: Sensitivity; SICUS: Small intestine contrast ultrasonography; Sp: Specificity.


**Table 4 Advantages and limitations of small bowel capsule endoscopy in Crohn’s disease**

|  |  |
| --- | --- |
| **Advantages** | **Limitations** |
| Less invasive than conventional endoscopy | Risk of capsule retention in stricturing CD |
| No need for sedation | No therapeutic or biopsy capability |
| High diagnostic yield comparable to other endoscopic or imaging modalities | SB evaluation may be incomplete due to:   * Uncontrolled air insufflation * Retention or delayed transition * Limited battery life * Impossible to maneuver |
| Direct mucosal evaluation | Longer procedure time compared to other modalities |
| Patient-friendly | Analysis is time-consuming for the physician |


CD: Crohn’s disease; SB: Small bowel.



**Figure 1 Small bowel capsule endoscopy findings associated with Crohn’s disease.** A: Edema; B: Aphthoid erosion; C: Superficial ulceration; D: Deep ulceration; E: Stenosis.



**Figure 2 Preferred reporting items for systematic reviews and meta-analyses diagram.**



**Figure 3 Potential usefulness of small bowel capsule endoscopy in a treat-to-target strategy for patients with Crohn’s disease.** Small bowel capsule endoscopy (SBCE) should help physician classify disease location and make a prognosis regarding future course of Crohn’s disease (CD) according to the presence of proximal small bowel lesions. SBCE should also be useful in the assessment of mucosal healing in patients with CD under treatment, and in the post-operative setting to detect post-operative recurrence in a timely manner.